Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Esperion surges on Phase IIb cholesterol-lowering data

This article was originally published in Scrip

Executive Summary

Esperion Therapeutics jumped 29.2% to a new all-time high of $99.60 per share on 17 March after the company reported that ETC-1002 lowered LDL cholesterol by up to 24% in combination with a low- to moderate-dose statin in a placebo-controlled Phase IIb clinical trial.

Advertisement

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028137

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel